HDAC1 and colorectal carcinoma: The compounds exerted enzymatic inhibitory activities against BRAFV600E and HDAC1/6 and suppressed the proliferation of CRC cells harboring both wild-type BRAF and mutated BRAFV600E [178] (Table 3).